Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14450594 | 1.00 | LTA4H (0.56) | LTA4HSYKALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL22911218 | 1.00 | LTA4H (0.56) | LTA4HSYKALDH1A1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL29400992 | 0.99 | LTA4H (0.55) | LTA4HSYKALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL14037218 | 0.91 | LTA4H (0.50) | LTA4HSYKALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL12155266 | 0.89 | LTA4H (0.61) | LTA4HSYKALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL7740147 | 0.89 | LTA4H (0.61) | LTA4HSYKALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL7740145 | 0.89 | LTA4H (0.61) | LTA4HSYKALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL24455841 | 0.88 | LTA4H (0.44) | LTA4HALDH1A1L3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL3501117 | 0.88 | LTA4H (0.60) | LTA4HSYKALDH1A1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL25286512 | 0.88 | LTA4H (0.60) | LTA4HSYKALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250249113-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | DEBIOPHARM RESEARCH & MANUFACTURING SA (CH) | 2025-08-07 | — | — | US | disclosed |
| WO-2025083205-A1 | DRUG COMBINATION COMPRISING ANTI-CD37 ANTIBODY MAYTANSINE CONJUGATE AND BCL2 INHIBITOR OR PI3K INHIBITOR | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-04-24 | — | — | WO | disclosed |
| EP-4507734-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | Debiopharm Research & Manufacturing S.A. (CH) | 2025-02-19 | — | — | EP | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| WO-2024105205-A1 | ANTIBODY-DRUG CONJUGATES (A2DCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |
| EP-4304655-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| EP-4271387-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF | Immunext, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023198884-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-10-19 | — | — | WO | disclosed |
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-27 | — | — | US | disclosed |
| EP-4136118-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Immunext, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022189859-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022150637-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | IMMUNEXT, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| WO-2021216913-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| US-8951959-B2 | Glucagon-like peptide-1 analogues and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2015-02-10 | — | — | US | disclosed |
| US-20130053304-A1 | GLUCAGON-LIKE PEPTIDE-1 ANALOGUES AND USES THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2013-02-28 | — | — | US | disclosed |
| US-5106951-A | Antineoplastic anthracyline agents intercalated with two aromatic side chains or an oligopeptide and covalently attached to an antibody | NEORX CORPORATION (US) | 1992-04-21 | — | — | US | disclosed |
| EP-0329184-A2 | Antimers and antimeric conjugation | NEORX CORPORATION (US) | 1989-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | LTA4H 393/4885SYK 4446/4885ALDH1A1 634/4885 |
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | SLC10A2, GPBAR1, NR1H4 | LTA4H 1295/4885SYK 2656/4885ALDH1A1 2119/4885 |
| US-20250249113-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | FCER2, FCGR2A, FCGR1A | LTA4H 1062/4885SYK 614/4885ALDH1A1 812/4885 |
| US-20130053304-A1 | GLUCAGON-LIKE PEPTIDE-1 ANALOGUES AND USES THEREOF | GLP1R, GCG, IAPP | LTA4H 2058/4885SYK 3770/4885ALDH1A1 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.